Pharmaceuticals
ACROBiosystems' new strategic focus - streamlining the transition from preclinical development to commercialization
BASEL, Switzerland, March 30, 2023 /PRNewswire/ -- ACROBiosystems has begun to narrow its focus into helping accelerate the process between preclinical, clinical and commercialization. With over 10 years development, ACROBiosystems continues to surprise and bring new solutions to the pharmaceutic...
2023-03-30 20:51
2723
Turn Biotechnologies Introduces its Dermatology Platform to the European Aesthetic Community at AMWC
MOUNTAIN VIEW, Calif., March 30, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, announced that it will for the first time share new data for its revolutionary dermatology platform with the interna...
2023-03-30 20:00
4235
DxVx Co., Ltd.'s affiliated company, Oxford Vacmedix (OVM) successfully completed Phase 1a in clinical trial of novel cancer vaccine OVM-200
SEOUL, South Korea, March 30, 2023 /PRNewswire/ -- DXVX announces that its affiliated company Oxford Vacmedix (OVM) has completed Phase 1a trial of cancer vaccine and plans to proceed Phase1b trial of OVM-200. DxVx Co., Ltd. is the Korean Stock market (KOSDAQ) listed company and is the largest s...
2023-03-30 17:39
2554
Great Place To Work unveils Best Workplaces in the Inaugural Singapore Healthcare and Biopharma List 2023
Employees express trust in leaders' competence and integrity and value fairness and impartiality as part of the workplace culture SINGAPORE, March 30, 2023 /PRNewswire/ -- Great Place To Work®, the global authority on workplace culture announced the 10 companies who are Best WorkplacesTM in its ...
2023-03-30 12:00
3024
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that as ofMarch 29, 2023, the company has conducted 13 clinical studies cover...
2023-03-30 08:00
3660
Athos Therapeutics Receives Regulatory Approval to Commence Phase I Clinical Trial of ATH-063
- ATH-063 is a novel, oral, first-in-class, small molecule therapeutic targeting both inflammation and direct mucosal healing in patients with ulcerative colitis and Crohn's disease - LOS ANGELES, March 30, 2023 /PRNewswire/ -- Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology ...
2023-03-30 03:32
3284
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia
BRATISLAVA, Slovakia, March 29, 2023 /PRNewswire/ -- BGI Genomics is pleased to announce the launch of COLOTECTTM 1.0 in Slovakia, in collaboration with its partner, Zentya. Zentya is a Slovak-based company that is passionate about providing patients with the latest technology in genetic screenin...
2023-03-29 16:00
1793
Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer
SUZHOU, China, March 29, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces that the U.S. Food an...
2023-03-29 14:00
3845
Antengene Announces First Patient Dosed with Claudin 18.2 Antibody-Drug Conjugate ATG-022 for the Treatment of Patients with Advanced or Metastatic Solid Tumors in Australia
* Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. * The Phase I CLINCH trial is designed to evaluate the safety, pharmacology, and preliminary efficacy of ATG-022 monotherapy in p...
2023-03-29 08:30
3139
Innovent Announces 2022 Annual Results and Business Updates
Building an Innovative Biopharmaceutical Company with Sustainable Growth and Comprehensive Capability ROCKVILLE, Md. and SUZHOU, China, March 29, 2023 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commer...
2023-03-29 08:00
5002
Antengene Announces Results for Full Year 2022 with Updates Highlighting a Sales Revenue Reaching 5.6 Times Year-Over-Year and Accelerated Global Innovation
SHANGHAI and HONG KONG, March 28, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), today announced its full-year 2022 financial results and provided updates on key events and achievements since the start of 2022. 1. Sales Revenue Reached 5.6 Times Year-Over-Year ...
2023-03-28 21:40
3097
Sirnaomics Announces 2022 Annual Results
Significant Progress in Clinical Trials for Core Products Reinforces Leading Position in RNA Therapeutics with Strong Product Pipeline Matrix Business Highlights * Clinical development * STP705 - The part-one Phase IIb interim data on STP705 for the treatment of isSCC was announced, with th...
2023-03-28 19:26
7813
Seegene declares to share Syndromic PCR technologies to prevent future pandemics
* Localization of Seegene Syndromic PCR technologies with global partners for versatile and proactive response to local emerging healthcare demands. * Formation of a collaborative global network to aggressively develop innovative syndromic PCR assays, challenging boundaries of PCR application....
2023-03-28 19:00
2477
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
First-in-Class ERAP1 Inhibitor Enters Clinical Development Study to Evaluate GRWD5769 as Monotherapy, as well as in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on...
2023-03-28 19:00
1927
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
SINGAPORE, March 28, 2023 /PRNewswire/ -- Becton Dickinson Holdings Pte Ltd (BD), a global leader in life science technologies, and the Agency for Science, Technology and Research (A*STAR),Singapore's lead public sector R&D agency, have announced an extended research partnership that will focus o...
2023-03-28 14:12
2605
Tavneos® (avacopan) included in updated EULAR recommendations for the management of AAV
Tavneos® newly introduced in the 2022 European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of ANCA-associated vasculitis (AAV) Recommendations recognize Tavneos®' ability to induce and sustain remission, lower glucocorticoids-induced toxic effects and pot...
2023-03-28 13:00
2948
HaemaLogiX to present final data from anti-KMA CAR-T preclinical studies at AACR
SYDNEY, March 28, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage biotech company developing novel immunotherapies for multiple myeloma, today announced that its anti-KMA CAR-T cell preclinical development has been completed and is the subject of an abstract accepted for poster presentation...
2023-03-28 09:43
2382
BioDuro-Sundia Announces Formation of Scientific Advisory Board
IRVINE, Calif., March 28, 2023 /PRNewswire/ -- BioDuro-Sundia, a leading drug discovery, development and commercial services organization backed by Advent International, announced today the establishment of a Discovery Research Scientific Advisory Board (SAB) with the appointment of Andrew Thomas...
2023-03-28 08:30
3527
Boan Biotech Announces 2022 Financial Results
Showing accelerated innovation and strong 225% revenue growth YANTAI, China, March 27, 2023 /PRNewswire/ -- Boan Biotech (6955.HK) today announced its 2022 financial results and recent business developments. 2022 business highlights * Record high in revenue: In 2022, Boan Biotech's revenue was...
2023-03-27 23:15
4847
YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study
* The trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical significance (95%CI: 2.1, 3.4, P<0.0001) based on interim data analysis * The tr...
2023-03-27 18:00
2170
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 317 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 256 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 250 media titles]
2026-02-16 08:00Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
8589
The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
2026-02-14 13:00
6798
U Power to Present at OTC Markets AI & Technology Investor Conference on February 19
2026-02-14 01:00
6679